Efficacy and safety of simeprevir with pegylated interferon alfa and ribavirin in patients with chronic hepatitis C
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2019
Price : $35 *
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2015 Planned initiation date changed from 1 Dec 2013 to 1 Dec 2014.
- 31 Jul 2015 Status changed from planning to not yet recruiting.
- 11 Nov 2013 New trial record